SEM images on fibrin network, image courtesy of Empa, 2016

Straumann® SLActive®

Performance beyond imagination.

SLActive® is Straumann’s high performance surface with extensive healing potential. It stands for high predictability and accelerated osseointegration^1-8. Recent studies show an outstanding clinical performance of SLActive® implants even in very challenging treatment protocols and patients with compromised health.^9-11

Survival rates

High and consistent survival rates between 95.1% and 98.8% documented by different studies after 5 and 10 year follow-up.^14-20

Bone preservation

Average bone loss of 0.5-1 mm after 10 years (baseline defined as implant loading time).^15,16

Low prevalence of peri-implantitis

Very low prevalence of peri-implantitis (1.8%) over the 10-year follow-up period.¹⁵

Brochures and videos

Looking for additional information? You'll find them in the Resource Center.

Featured stories on youTooth

Contact us

Name*

E-mail*

Location*

Your message*

Data usage agreement*

I acknowledge that my data will be processed according to the terms and conditions of the privacy notice.

Read our privacy notice.

Captcha*

Please retype the code above

References

1 Straumann SLActive implants compared to Straumann SLA implants. Lang NP, Salvi GE, Huynh-Ba G, Ivanovski S, Donos N, Bosshardt DD. Early osseointegration to hydrophilic and hydrophobic implant surfaces in humans. Clin Oral Implants Res. 2011 Apr;22(4):349-56. doi: 10.1111/j.1600-0501.2011.02172.x.
2 Rupp F, Scheideler L, Olshanska N, de Wild M, Wieland M, Geis-Gerstorfer J. Enhancing surface free energy and hydrophilicity through chemical modification of microstructured titanium implant surfaces. Journal of Biomedical Materials Research A, 76(2):323-334, 2006.
3 De Wild M. Superhydrophilic SLActive® implants. Straumann document 151.52, 2005; Katharina Maniura. Laboratory for Materials – Biology Interactions Empa, St. Gallen, Switzerland, Protein and blood adsorption on Ti and TiZr implants as a model for osseointegration. EAO 22nd Annual Scientific Meeting, October 17 – 19 2013, Dublin. Kopf BS, Schipanski A, Rottmar M, Berner S, Maniura-Weber K, Enhanced differentiation of human osteoblasts on Ti surfaces pre-treated with human whole blood. Acta Biomaterialia. 2015 June; 19: 180–190. Kopf BS, Ruch S, Berner S, Spencer ND, Maniura-Weber K, The role of nanostructures and hydrophilicity in osseointegration: In-vitro protein-adsorption and blood-interaction studies. J Biomed Mater Res A. 2015 August; 103 (8): 2661-2672.
4 Schwarz, F., et al., Bone regeneration in dehiscence-type defects at non-submerged and submerged chemically modified (SLActive®) and conventional SLA® titanium implants: an immunohistochemical study in dogs. J Clin. Periodontol. 35.1 (2008): 64–75.
5 Rausch-fan X, Qu Z, Wieland M, Matejka M, Schedle A. Differentiation and cytokine synthesis of human alveolar osteoblasts compared to osteoblast-like cells (MG63) in response to titanium surfaces. Dental Materials 2008 Jan;24(1):102-10. Epub 2007 Apr 27.
6 Schwarz F, Herten M, Sager M, Wieland M, Dard M, Becker J. Histological and immunohistochemical analysis of initial and early osseous integration at chemically modified and conventional SLA® titanium implants: Preliminary results of a pilot study in dogs. Clinical Oral Implants Research, 11(4): 481-488, 2007.
7 Raghavendra S, Wood MC, Taylor TD. Int. J. Oral Maxillofac. Implants. 2005 May–Jun;20(3):425–31. 9.
8 Oates TW, Valderrama P, Bischof M, Nedir R, Jones A, Simpson J, Toutenburg H, Cochran DL. Enhanced implant stability with a chemically modified SLA® surface: a randomized pilot study. Int. J. Oral Maxillofac. Implants. 2007;22(5):755–760.
9 Nicolau P, Guerra F, Reis R, Krafft T, Benz K , Jackowski J 10-year results from a randomized controlled multicenter study with immediately and early loaded SLActive implants in posterior jaws. Presented at 25th Annual Scientific Meeting of the European Association of Osseointegration – 29 Sep – 1 Oct 2016, Paris.
10 Nelson, K., Stricker, A., Raguse, J.-D. and Nahles, S. (2016), Rehabilitation of irradiated patients with chemically modified and conventional SLA implants: a clinical clarification. J Oral Rehabil, 43: 871–872. doi:10.1111/joor.12434.
11 Patients treated with dental implants after surgery and radio-chemotherapy of oral cancer. Heberer S, Kilic S, Hossamo J, Raguse J-D, Nelson K. Rehabilitation of irradiated patients with modified and conventional sandblasted, acid-etched implants: preliminary results of a split-mouth study. Clin. Oral Impl. Res. 22, 2011; 546–551.
12 Straumann (2016). SLActive® supports enhanced bone formation in a minipig surgical GBR model with coronal circumferential defects. Unpublished data.